The story of Zimmer Biomet began in 1927 in Warsaw, Indiana, when Justin O. Zimmer, an ambitious orthopedic salesman, founded Zimmer Manufacturing Company to produce lightweight aluminum fracture splints. Prior to Zimmer's invention, broken limbs were immobilized using heavy, cumbersome wood or plaster. Zimmer's aluminum splints provided superior radiographic transparency and patient mobility, rapidly gaining adoption across American hospitals. Throughout the mid-20th century, Zimmer expanded into hip prostheses and knee joint implants, pioneering the revolutionary Charnley-type hip replacement in the US. In 1972, Zimmer was acquired by Bristol-Myers Squibb, operating as a corporate subsidiary until it was spun off as an independent public company listed on the New York Stock Exchange in 2001. In 2015, Zimmer executed a transformative $13.4 billion mega-merger with cross-town Warsaw rival Biomet, creating Zimmer Biomet Holdings and uniting two of the world's most storied orthopedic portfolios. In 2016, Zimmer Biomet acquired French robotics pioneer Medtech SA, securing the foundational technology for the ROSA robotic surgical platform, which now anchors its global knee, hip, and neurosurgical procedures. In the decades following its initial founding, Zimmer Biomet navigated rapid industry evolutions, transitioning from early legacy operating paradigms to modern integrated operations. This sustained focus allowed the company to survive cyclical macroeconomic contractions, outpace regional incumbents, and establish deep institutional trust with demanding stakeholders. Through disciplined capital allocation, continuous internal innovation, and targeted strategic initiatives, Zimmer Biomet built an enduring competitive moat anchored by proprietary technology, deep domain expertise, and sticky relationships that resist structural disruption.